MCK — McKesson Corporation

McKesson Corporation Q3 Fiscal 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased 11% year-over-year to $106.2 billion.
• Adjusted EPS: Rose 16% to $9.34, driven by strong operational performance.
• Gross Profit: Increased 10% to $3.7 billion.
• Operating Profit: Grew 13% to $1.7 billion.
• Free Cash Flow: Reported at $1.1 billion for the quarter; trailing twelve months totaled $9.6 billion.
• Share Repurchases: Returned $781 million to shareholders, including $680 million in share buybacks.

2. Strategic Updates and Business Highlights

• Growth Areas: Continued momentum in oncology, biopharma services, and North American distribution, particularly in specialty products.
• Oncology Segment: Revenue surged 37% to $13 billion, with a 57% increase in operating profit, bolstered by acquisitions of Prism Vision and Core Ventures.
• Pharmaceutical Distribution: North American segment revenue increased 9% to $88.3 billion, with a notable 26% growth in GLP-1 distribution.
• Technology Investments: Focus on automation and AI to enhance operational efficiency and customer experience, including significant improvements in patient support capabilities.
• Separation of Medical-Surgical Business: Progressing towards an IPO by the second half of 2027; divested Norwegian operations.

3. Forward Guidance and Outlook

• Full-Year EPS Guidance: Raised to $38.80 - $39.20, reflecting 17-19% growth year-over-year.
• Revenue Growth: Expected to be between 12-16% for the full year.
• Operating Profit Growth: Anticipated at 13-17%.
• Segment Outlook:
  • North American Pharmaceutical: Revenue growth of 10-14%.
  • Oncology and Multispecialty: Revenue growth of 29-33%.
  • Prescription Technology Solutions: Revenue growth of 9-13%.

4. Bad News, Challenges, or Points of Concern

• Market Variability: Concerns about the impact of regulatory changes, particularly related to the Inflation Reduction Act and potential pricing pressures from branded drug manufacturers.
• Illness Season Demand: Noted soft demand in the fiscal third quarter, which could impact future performance.
• Operating Margin Variability: Some fluctuations in margins were observed, particularly in the oncology segment, which may reflect integration challenges or market dynamics.

5. Notable Q&A Insights

• Technology Investments: Executives emphasized the positive impact of technology and automation on productivity, particularly during the annual verification season.
• Long-Term Margin Improvement: There is optimism about improving margins in the prescription technology segment through ongoing automation and efficiency initiatives.
• Competitive Position: Management highlighted their strong relationships with manufacturers and confidence in navigating the evolving regulatory landscape.
• Future Growth Drivers: The introduction of oral GLP-1 medications and the expansion of access and affordability programs were discussed as key growth opportunities.

Overall, McKesson Corporation reported a strong quarter, with significant growth across its core business segments and a positive outlook for the remainder of the fiscal year, despite some challenges related to market variability and regulatory pressures.